Gary M. Simon

Chatterjee Management Co (Chatterjee Management) is a private equity subsidiary of The Chatterjee Group founded in 1989 by Purnandu Chatterjee. The firm is headquartered in New York with additional offices in Bombay, Delhi and Calcutta.

ACI Capital Co. LLC (ACI Capital) is a private equity subsidiary of Ingleside Investors LLC founded in 1995 by Kevin S. Penn. The firm is headquartered in New York.

RevH2O LLC engages in the construction business. The company was founded by Michael Lee Clofine and David Erland Kailbourne and is headquartered in Pittsford, NY.

Leucadia Asset Management LLC (LAM) is a SEC-registered investment advisor headquartered in New York City. The firm was founded in 2002 as Jefferies Private Client Advisers LLC. They changed their name to Jefferies Investment Advisers LLC in 2006 and to Leucadia Asset Management LLC in 2021. The firm is a wholly owned subsidiary of Jefferies Financial Group, Inc. (NYSE: JEF). LAM provides advisory services to high net-worth individuals, trusts, estates, foundations, charitable organizations, corporations and other business entities.

Founded in 1987, SAMCO Capital Markets, Inc. is a broker/dealer headquartered in Austin, Texas with additional offices in Dallas, Houston, San Antonio, New York City and Edmund, Oklahoma. The firm specializes in serving financial institutions. Their expertise lies in public finance and trading, institutional sales, taxable fixed-income trading, high yield and public funds management. SAMCO provides advisory services to issuers of municipal debt in the Southwest and Southeast U.S. Their traders and underwriters make primary and secondary markets in municipal bonds on a national basis. The firm provides advisory services to issuers of municipal debt in the Southwestern and Southeastern U.S. SAMCO's institutional sales department provides coverage of both tier-one national accounts, regional banks and trust departments. They are a leading distributor in the Southwestern U.S. for bank-qualified new issuances. The firm is active in trading and positioning taxable fixed-income securities, including U.S. Treasuries, Agencies, mortgage backed securities, collateralized mortgage obligations, corporate securities and municipal bonds, including high yield. SAMCO's public funds management group specializes in investment, financial management and banking for public entities such as counties, cities and school districts.

Aton Pharma, Inc. develops therapeutics for cancer and other diseases. Its products include Edecrin, Sodium Edecrin, Cuprimine, Demser and Syprine. The company was founded by Michael G. Wells in 2001 and is headquartered in Lawrenceville, NJ.

Cerberus Capital Management LP (Cerberus) is a private equity firm founded in 1992 by Stephen A. Feinberg and William L. Richter. It is headquartered in New York.

FMR LLC engages in the provision of financial and investment services. It offers financial planning and advice, wealth management, retirement plans, trading and brokerage services, and investment products. The company was founded by Edward C. Johnson II in 1946 and is headquartered in Boston, MA.

DFW Real Estate Group, Inc. provides real estate brokerage services. It provides its services through the following companies DFW Real Estate, DFW Funding Solutions, DFW Relo Solutions, DFW Corporate Housing Solutions, Acquisition Management Group (AMG), Stewart Title, Coppermark Bank, and CNR Insurance Brokerage Services. The company was founded in 1997 and is headquartered in Dallas, TX.

Part of Aseko, Inc., Glytec LLC is a healthcare provider company that specializes in improving the quality and cost of care for diabetes patients. The company, founded in 2006 by Robby Booth, is based in Waltham, MA, and has Edmond L. Furlong as its CEO since 2018. Glytec's FDA-cleared titration software and proprietary algorithms deliver personalized diabetes treatment recommendations across the continuum of care, from hospital to home. The company's eGlycemic Management System (eGMS) is an EHR-integrated cloud-based software solution that supports safe and effective glycemic management and insulin dosing. Glytec supports the transition from sliding scale to basal bolus insulin for standardization of insulin therapy across critical and non-critical care settings. The safety and efficacy of Glytec's solutions have been validated by several dozen studies published in medical journals and presented at scientific conferences.